Hardman Johnston Global Advisors LLC Has $72.27 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Hardman Johnston Global Advisors LLC lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQVFree Report) by 1.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 312,355 shares of the medical research company’s stock after selling 3,781 shares during the quarter. IQVIA accounts for approximately 2.3% of Hardman Johnston Global Advisors LLC’s holdings, making the stock its 16th largest holding. Hardman Johnston Global Advisors LLC owned 0.17% of IQVIA worth $72,273,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in IQV. AdvisorNet Financial Inc raised its stake in shares of IQVIA by 327.6% in the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 95 shares during the period. BKM Wealth Management LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at about $32,000. ST Germain D J Co. Inc. acquired a new stake in shares of IQVIA in the 2nd quarter valued at about $33,000. Activest Wealth Management acquired a new stake in shares of IQVIA in the 4th quarter valued at about $35,000. Finally, Live Oak Investment Partners acquired a new stake in shares of IQVIA in the 4th quarter valued at about $41,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

IQVIA stock traded down $3.79 during midday trading on Friday, reaching $234.23. 892,876 shares of the company’s stock were exchanged, compared to its average volume of 983,311. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The firm has a market cap of $42.51 billion, a price-to-earnings ratio of 32.05, a P/E/G ratio of 2.32 and a beta of 1.50. The stock’s 50-day simple moving average is $243.00 and its 200 day simple moving average is $220.38. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86.

IQVIA (NYSE:IQVGet Free Report) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The company had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. During the same quarter in the previous year, the company posted $2.54 earnings per share. The business’s revenue was up 3.5% on a year-over-year basis. On average, analysts expect that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on IQV shares. BTIG Research started coverage on IQVIA in a research note on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price target on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. Barclays lifted their target price on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Truist Financial lifted their target price on IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Finally, Evercore ISI lifted their target price on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a research report on Thursday, February 15th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.80.

Check Out Our Latest Research Report on IQVIA

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the sale, the insider now owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the sale, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The disclosure for this sale can be found here. Insiders sold a total of 41,285 shares of company stock worth $10,331,003 over the last quarter. Company insiders own 1.60% of the company’s stock.

IQVIA Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Stories

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVFree Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.